PDGFRB and Hand-foot syndrome: On the contrary, HFS is not observed under vandetanib, that does not inhibits PDGFR, but occurs very frequently under sorafenib and lenvatinib treatment because of their ability to inhibit both VEGFR and PDGFR (Supplementary Table 2) (25, 26, 27, 28, 29, 30).